APLI — Appili Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$3.64m
- CA$14.74m
- CA$0.83m
Annual income statement for Appili Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.199 | 0 | 1.39 | 0.334 | 0.827 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 6.29 | 15.7 | 26 | 8.25 | 8.88 |
| Operating Profit | -6.09 | -15.7 | -24.6 | -7.91 | -8.05 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.42 | -14.3 | -25.1 | -9.21 | -3.71 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.42 | -14.3 | -25.1 | -9.24 | -3.78 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.42 | -14.3 | -25.1 | -9.24 | -3.78 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.42 | -14.3 | -25.1 | -9.24 | -3.78 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.158 | -0.242 | -0.376 | -0.081 | -0.031 |